Contineum reports Q4 2024 net loss of $14.6M, cash $204.8M, runway through 2027

Contineum Therapeutics, Inc.

Net loss $14.6M in Q4 2024 vs $7.8M in Q4 2023; R&D expenses $13M (+62% YoY).
Cash and equivalents $204.8M at Dec 31, 2024; expects to fund operations through 2027.
Topline data from PIPE-791 Phase 1b PET trial expected Q2 2025; PIPE-307 Phase 2 RRMS data H2 2025.
PIPE-791 Phase 2 proof-of-concept in IPF and PrMS planned H2 2025 pending toxicity studies.
Plan to file IND for CTX-343 in H2 2025; J&J recruiting Phase 2 MDD trial of PIPE-307.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.